Quick Answer
Traws Pharma, Inc. reported Total Revenue of $226.0 thousand for fiscal year 2024.
Traws Pharma, Inc. — Key Financials by Year
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Total Revenue | $226.0K +0.0% |
$226.0K +0.0% |
$226.0K +0.0% |
$226.0K -2.2% |
$231.0K -89.4% |
$2.18M +77.8% |
| Net Income | -$166.52M -778.8% |
-$18.95M | — | — | — | -$21.50M -4.5% |
| Diluted EPS | -$35.21 -56.0% |
-$22.57 -2380.2% |
-$0.91 +5.2% |
-$0.96 +55.8% |
-$2.17 | — |
| Total Assets | $24.96M +10.0% |
$22.68M -42.4% |
$39.37M -29.0% |
$55.48M +177.6% |
$19.99M -15.6% |
$23.67M +32.1% |
| Cash and Equivalents | — | — | — | — | — | — |
| Stockholders Equity | -$31.63M -396.4% |
$10.67M -62.3% |
$28.31M -38.6% |
$46.12M +646.9% |
$6.17M -46.6% |
$11.57M +114.9% |
| R&D Expense | — | $11.43M +0.2% |
$11.41M +56.3% |
$7.30M -56.8% |
$16.90M +8.8% |
$15.54M -8.2% |
| Operating Income | -$142.37M -601.4% |
-$20.30M -3.4% |
-$19.63M -19.0% |
-$16.50M +34.0% |
-$24.99M -15.2% |
-$21.70M +6.8% |
| Shares Outstanding | 3.65M +334.5% |
840,251 -96.0% |
20.93M +0.1% |
20.90M -87.5% |
167.26M +50.5% |
111.17M +1859.2% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | June 30, 2025 | $2.73M | +4694.7% | +4694.7% |
| Net Income | September 30, 2025 | -$3.96M | +53.3% | -333.0% |
| Diluted EPS | September 30, 2025 | -$0.34 | +77.2% | -209.1% |
| Total Assets | September 30, 2025 | $12.44M | +39.2% | -20.3% |
| Cash and Equivalents | September 30, 2017 | $7.60M | -70.5% | -49.3% |
| Stockholders Equity | September 30, 2025 | $4.54M | +323.6% | -45.0% |
| R&D Expense | March 31, 2024 | $1.91M | -53.1% | -22.3% |
| Operating Income | September 30, 2025 | -$4.05M | +52.5% | -224.7% |
| Shares Outstanding | September 30, 2025 | 7.13M | +135.7% | +0.9% |
- Traws Pharma, Inc. reported Total Revenue of $226.0 thousand for fiscal year 2024.
- Traws Pharma, Inc. showed an increase of +0.0% in Total Revenue compared to the prior fiscal year.
- Traws Pharma, Inc. reported Net Income of -$166.52 million for fiscal year 2024.
- Traws Pharma, Inc. showed a decrease of -778.8% in Net Income compared to the prior fiscal year.
- Traws Pharma, Inc. reported Diluted EPS of $35.21 per share (loss) for fiscal year 2024.
- Traws Pharma, Inc. showed a decrease of -56.0% in Diluted EPS compared to the prior fiscal year.
- Traws Pharma, Inc. reported Total Assets of $24.96 million for fiscal year 2024.
- Traws Pharma, Inc. showed an increase of +10.0% in Total Assets compared to the prior fiscal year.
- Traws Pharma, Inc. reported Cash and Equivalents of $21.40 million for fiscal year 2016.
- Traws Pharma, Inc. showed an increase of +8.1% in Cash and Equivalents compared to the prior fiscal year.
- Traws Pharma, Inc. reported Stockholders Equity of -$31.63 million for fiscal year 2024.
- Traws Pharma, Inc. showed a decrease of -396.4% in Stockholders Equity compared to the prior fiscal year.
- Traws Pharma, Inc. reported R&D Expense of $11.43 million for fiscal year 2023.
- Traws Pharma, Inc. showed an increase of +0.2% in R&D Expense compared to the prior fiscal year.
- Traws Pharma, Inc. reported Operating Income of -$142.37 million for fiscal year 2024.
- Traws Pharma, Inc. showed a decrease of -601.4% in Operating Income compared to the prior fiscal year.
- Traws Pharma, Inc. reported Shares Outstanding of 3.65 million shares for fiscal year 2024.
- Traws Pharma, Inc. showed an increase of +334.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: